Comparison Of Outcome Of Microneedling With Autologous PRP Vs Microneedling With Topical Insulin In Treatment Of Post Acne Atrophic Scars.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06002854 |
Recruitment Status :
Completed
First Posted : August 21, 2023
Last Update Posted : August 21, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
ATROPHIC ACNE SCARS | Drug: PRP( platelet rich plasma) and Insulin human | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 50 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Comparison Of The Outcome Of Treatment of Microneedling With Autologous Platelet- Rich -Plasma Versus Microneedling With Topical Insulin In The Treatment Of Post Acne Atrophic Scars. |
Actual Study Start Date : | August 1, 2022 |
Actual Primary Completion Date : | December 1, 2022 |
Actual Study Completion Date : | February 1, 2023 |
Arm | Intervention/treatment |
---|---|
Experimental: GROUP A Microneedling with PRP(platelete rich plasma) |
Drug: PRP( platelet rich plasma) and Insulin human
Microneedling with autologus PRP reduces inflammationin acne scars. Insulin human is a new topical drug which is used nowadays for acne scars as it is more effective in producing collagen formation as well as new blood vessel formation |
Experimental: GROUP B Microneedling with topical INSULIN |
Drug: PRP( platelet rich plasma) and Insulin human
Microneedling with autologus PRP reduces inflammationin acne scars. Insulin human is a new topical drug which is used nowadays for acne scars as it is more effective in producing collagen formation as well as new blood vessel formation |
- Efficacy of Topical Insulin R with microneedling versus Platelets rich plasma in atrophic acne scars [ Time Frame: Efficacy will be assesed upto 4 months. ]Efficacy will be assessed by using Goodman and Baron Qualitative Scar Grading System
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years to 50 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- postacne atrophic scars ≥ 2 on Goodman and Baron's acne scar-grading system
- Either gender.
- Age 20-50 years.
Exclusion Criteria:
- lactation and pregnancy
- skin cancers and infection
- photosensitivity like SLE ,XP
- use of RETINOIDS in last 6 months.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06002854
Pakistan | |
JPMC | |
Karachi, Sindh, Pakistan |
Principal Investigator: | KHADIJA ASADULLAH, MBBS | JPMC | |
Principal Investigator: | FAIZA INAM, FCPS | JPMC | |
Principal Investigator: | PARISA SANAWAR, FCPS | JPMC |
Responsible Party: | Nazia Jabeen, Principal Investigator, Jinnah Postgraduate Medical Centre |
ClinicalTrials.gov Identifier: | NCT06002854 |
Other Study ID Numbers: |
NO.F.2-81/2022-GENL/252/JPMC |
First Posted: | August 21, 2023 Key Record Dates |
Last Update Posted: | August 21, 2023 |
Last Verified: | June 2023 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Atrophy Pathological Conditions, Anatomical Insulin |
Insulin, Globin Zinc Hypoglycemic Agents Physiological Effects of Drugs |